Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,018 Mln
P/E Ratio
--
P/B Ratio
8.87
Industry P/E
--
Debt to Equity
1.41
ROE
-0.37 %
ROCE
-15.99 %
Div. Yield
0 %
Book Value
4.7
EPS
-1.83
CFO
$-452.83 Mln
EBITDA
$-447.33 Mln
Net Profit
$-556.24 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
| -1.33 | -13.23 | -14.16 | 69.86 | 16.70 | 21.50 | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
| 39.69 | 51.38 | 22.26 | -8.65 | -28.79 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and... minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. Read more
CEO & Director
Mr. Christopher Peetz
CEO & Director
Mr. Christopher Peetz
Headquarters
Foster City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mirum Pharmaceuticals Inc (MIRM) stood at $ 671 Mln as on 31-Dec-24
The share price of Mirum Pharmaceuticals Inc (MIRM) is $40.80 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Mirum Pharmaceuticals Inc (MIRM) has given a return of 16.7% in the last 3 years.
Mirum Pharmaceuticals Inc (MIRM) has a market capitalisation of $ 2,018 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Mirum Pharmaceuticals Inc (MIRM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mirum Pharmaceuticals Inc (MIRM) and enter the required number of quantities and click on buy to purchase the shares of Mirum Pharmaceuticals Inc (MIRM).
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
The CEO & director of Mr. Christopher Peetz. is Mirum Pharmaceuticals Inc (MIRM), and CFO & Sr. VP is Mr. Christopher Peetz.
There is no promoter pledging in Mirum Pharmaceuticals Inc (MIRM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Mirum Pharmaceuticals Inc. (MIRM) | Ratios |
|---|---|
|
Return on equity(%)
|
-37.08
|
|
Operating margin(%)
|
-21.55
|
|
Net Margin(%)
|
-26.1
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mirum Pharmaceuticals Inc (MIRM) was $0 Mln.
$0.33
(
